We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Iknowa is a property improvement marketplace that connects and matches property owners with individuals or companies who provide property services. The company aims to be the go-to support platform for all building and renovation projects. Iknowa allows users to post jobs free of cost on its portal. The company has featured in publications like FinTech, Business Money and Showhouse. They have successfully raised over £250,000 to date. Iknowa will use 50% of the investment to maintain, improve & build new technology by the first quarter of 2021, 30% as operational costs, and 20% for sales and marketing.
days to go: Expired investment: £196,240
Bua Fit is easy to use, a simple way to book web application for outdoor fitness classes. It eliminates all the trouble by connecting the trainers to clients for group fitness classes and gives the customers a diversity of trainers. The company has been a finalist in The Great British Entrepreneurial Challenge, has a network of 100 trainers and 42% active user rate since launch. With the proceeds, the company will earn more users, more trainers, more revenue, invest in product development and expand the team.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £205,378
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap. 

Pitch Rated

56%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £199,227
WorkClub converts under-used real estate into productive co-working areas and provides an affordable membership for remote workers across London. The company has 500+ members, 800+ guests and 25 WorkClub’s spaces in London. WorkClub has also secured many venues across the UK with Young's, Hippo Inns and more. Furthermore, it is listed as a ‘Top 10 startup to watch’ by TechRound, has 4.8* rating on TrustPilot and, acquired 30 businesses to offer discounted WorkClub memberships to members including ZipCar, PureGym. The company will use the funds to develop WorkClub’s technology and to expand its offering into other key UK cities.
days to go: Expired investment: £342,820
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £166,670
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go: Expired investment: £355,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph